(ZNTL) – Press Releases
-
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
-
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
-
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
-
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
-
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
-
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
-
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
-
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
-
Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combination
-
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
-
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from
-
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
-
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates
-
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
-
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
-
Newman Ferrara LLP Announces Corporate Governance Investigations of Zentalis Pharmaceuticals, Inc. (ZNTL)
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
-
Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer
-
Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer
-
Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer
-
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
-
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
-
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
-
Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference
-
Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary
-
Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference
Back to ZNTL Stock Lookup
